drugset
drugset / Trial / NCT07304128

A Study of PLB-002 in Advanced Solid Tumors

NCT07304128 ↗

Phase 1 Recruiting 100 enrolled Primelink BioTherapeitics(ShenZhen) Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will test the safety, including side effects, and determine the characteristics of a drug called PLB-002 in participants with solid tumors.

Timeline

Start
2026-02-06
Primary completion
2027-06-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject PLB-002 Unknown — —

Indications

neoplasm